Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TTP and ADAMTS13: When Is Testing Appropriate?

Pier Mannuccio Mannucci1, Flora Peyvandi

  • 1The University of Milan , Via Pace 9, 20122 Milano, Italy. piermannuccio.mannucci@unimi.it

Hematology. American Society of Hematology. Education Program
|November 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bleeding and thrombotic events and intensity of heparin therapy in the two first waves of COVID-19.

Internal and emergency medicine·2024
Same author

D-dimer for patients on VKA vs DOAC: impact on the validity of D-dimer to make decision for extended anticoagulation.

Blood advances·2024
Same author

Assessing joint health in haemophilia patients: The combined value of physical examination and ultrasound imaging.

Haemophilia : the official journal of the World Federation of Hemophilia·2024
Same author

Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2024
Same author

ISTH's new strategic plan 2024-2028: A transformative journey toward shaping the future of thrombosis and hemostasis.

Journal of thrombosis and haemostasis : JTH·2024
Same author

Gender equity in hemophilia: need for healthcare, familial, and societal advocacy.

Frontiers in medicine·2024
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Thrombotic thrombocytopenic purpura (TTP) is linked to ADAMTS13 enzyme deficiency, which affects von Willebrand factor regulation. Understanding this enzyme is key to diagnosing and treating TTP effectively.

Area of Science:

  • Hematology
  • Molecular Medicine
  • Pathophysiology

Background:

  • Thrombotic thrombocytopenic purpura (TTP) is a critical condition involving microangiopathic hemolytic anemia, low platelets, and organ failure.
  • Recent research focuses on the pathophysiology of TTP, particularly the role of the ADAMTS13 enzyme.
  • ADAMTS13 regulates the size of von Willebrand factor (VWF), crucial for platelet function in blood vessels.

Purpose of the Study:

  • To review the pathophysiology of TTP over the last decade.
  • To highlight the significance of ADAMTS13 in TTP pathogenesis.
  • To address the heterogeneity in acquired TTP and its implications for treatment.

Main Methods:

  • Review of studies on TTP pathophysiology.
  • Analysis of ADAMTS13's role in VWF cleavage.

Related Experiment Videos

  • Examination of plasma ADAMTS13 levels in inherited and acquired TTP.

    • Main Results:

    • Severe ADAMTS13 deficiency is characteristic of inherited TTP.
    • Acquired TTP exhibits significant clinical and laboratory variability.
    • Some acquired TTP cases show measurable plasma ADAMTS13 levels, challenging traditional understanding.

    Conclusions:

    • ADAMTS13 deficiency is central to TTP, impacting VWF regulation and microcirculation.
    • The heterogeneity of acquired TTP complicates diagnosis and therapeutic strategies.
    • Further research is needed to fully elucidate TTP pathogenesis and optimize patient care.